US EditionIt Is Short, Again, Consolidated Purchase of Medicinal Products
6 Articles
6 Articles
Reforma
The parastatal Birmex did not manage to assign half of the keys to the consolidated tender of drugs and inputs for 2026.
Laboratorios de Biológicos y Reactivos de México (Birmex) would have failed to award the purchase of medicines by 2026, so it is possible that they will be allocated directly.According to the information, Birmex failed to agree on 50% of the contracts for the purchase of supplies and medicines by 2026, which have already been declared as “deserts”. They foresee direct awards for the purchase of medicines in 2026 after Birmex's failureThe parasta…
Laboratorio de Biológicos y Reactivos de México (Birmex) failed to award 1026 keys of drugs and inputs in the consolidated purchase 2025-2026. This represents that the parastatal company was only able to obtain 50.5% of the keys that it proposed to acquire, that is, 2 thousand 029 keys. The Anticorruption and Good Government Secretariat announced the details of the consolidated purchase, which again did not succeed, after in March 2025, the purc…
• Only 50.5% of the keys foreseen in the consolidated purchase were awarded• One thousand 26 keys did not obtain a contract due to lack of offers or prices out of budget• The process carries background for possible irregularities and cost overruns The consolidated purchase of medicines and health inputs corresponding to fiscal years 2025-2026 again recorded limited results in Laboratorios de Biológicos y Reactivos de México (Birmex), which left …
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
